Showing results (471-480 of 554) with videos related to
Sort By:
Pageof 56
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.Seminars in Surgical Oncology|August 19, 2003
New TNM melanoma staging system: linking biology and natural history to clinical outcomesCharles M Balch, Antonio C Buzaid, Seng-Jaw Soong, et al.Gastroenterology|December 11, 2020
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in MiceIvana Peran, Sivanesan Dakshanamurthy, Matthew D McCoy, et al.Cancer|March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, M B Atkins, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.Pageof 56